MCID: ART017
MIFTS: 56

Aortic Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Aortic Disease

MalaCards integrated aliases for Aortic Disease:

Name: Aortic Disease 12 15 17
Aortic Diseases 56 45 74
Disorder of the Aorta 12
Aortic Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:520
MeSH 45 D001018
NCIt 51 C101253
SNOMED-CT 69 47040006
ICD10 34 I35.9
UMLS 74 C0003493

Summaries for Aortic Disease

Disease Ontology : 12 An artery disease that is characterized by degeneration of the cells composing the aortic wall.

MalaCards based summary : Aortic Disease, also known as aortic diseases, is related to aortic aneurysm, familial thoracic 2 and familial thoracic aortic aneurysm and dissection. An important gene associated with Aortic Disease is FBN1 (Fibrillin 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Acetazolamide and Morphine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and spinal cord, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Aortic Disease

Diseases related to Aortic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 157, show less)
# Related Disease Score Top Affiliating Genes
1 aortic aneurysm, familial thoracic 2 30.4 ACTA2 FBN1
2 familial thoracic aortic aneurysm and dissection 30.3 FBN1 TGFBR1 TGFBR2
3 marfan syndrome 30.3 ACTA2 ELN FBN1 MMP2 TGFBR1 TGFBR2
4 aortic aneurysm 30.2 ACTA2 EFEMP2 ELN FBN1 MYH11 MYLK
5 aortic aneurysm, familial thoracic 6 30.0 ACTA2 MYH11 MYLK
6 arterial tortuosity syndrome 29.9 EFEMP2 ELN TGFBR1
7 loeys-dietz syndrome 4 29.9 TGFB2 TGFBR1 TGFBR2
8 loeys-dietz syndrome 1 29.5 FBN1 MYH11 TGFB2 TGFBR1 TGFBR2
9 varicose veins 29.4 ELN MMP2 MMP9
10 aortic aneurysm, familial abdominal, 1 29.3 APOE ELN FBN1 MMP2 MMP9
11 loeys-dietz syndrome 29.3 ACTA2 FBN1 MYH11 MYLK TGFB2 TGFBR1
12 sleep apnea 29.3 APOE CRP IL6 REN
13 aortic valve disease 1 29.2 ACTA2 CRP ELN FBN1 NOTCH1 REN
14 inguinal hernia 29.1 ELN FBN1 IL6 MMP2 MMP9
15 takayasu arteritis 29.1 CRP IL6 MMP9
16 heart valve disease 29.1 CRP ELN FBN1 REN
17 arteries, anomalies of 29.0 APOE CRP IL6 MMP9 REN
18 loeys-dietz syndrome 3 28.9 ACTA2 FBN1 MYH11 MYLK PRKG1 TGFB2
19 tetralogy of fallot 28.7 CRP FBN1 MMP9 NOTCH1 REN
20 heart disease 28.7 APOE CRP ELN IL6 NOTCH1 REN
21 aortic aneurysm, familial thoracic 1 28.2 ACTA2 EFEMP2 ELN FBN1 MMP2 MYH11
22 heritable thoracic aortic disease 12.2
23 calcific aortic disease with immunologic abnormalities, familial 12.0
24 aorta atresia 10.9
25 pseudoxanthoma elasticum-like papillary dermal elastolysis 10.5 ELN FBN1
26 late-onset focal dermal elastosis 10.5 ELN FBN1
27 char syndrome 10.4 ACTA2 FBN1 TGFBR2
28 familial abdominal aortic aneurysm 10.4 ELN FBN1 MYLK
29 acute adrenal insufficiency 10.4 IL6 REN
30 aortic valve insufficiency 10.3 ELN FBN1 NOTCH1
31 cerebral arterial disease 10.3 ACTA2 ELN MMP9
32 chronic actinic dermatitis 10.3 ELN FBN1 MMP9
33 cutis laxa, autosomal recessive, type ib 10.2 EFEMP2 ELN
34 connective tissue disease 10.2 ACTA2 ELN FBN1 IL6
35 exfoliation syndrome 10.2 APOE ELN FBN1
36 extracranial arteriovenous malformation 10.2 MMP2 MMP9
37 sorsby fundus dystrophy 10.2 ELN FBN1 MMP2
38 diabetic foot ulcers 10.2 IL6 MMP9
39 focal myositis 10.2 MMP2 MMP9
40 cutis laxa, autosomal recessive, type ic 10.2 EFEMP2 TGFBR1 TGFBR2
41 villous adenocarcinoma 10.2 MMP2 MMP9
42 spastic entropion 10.2 MMP2 MMP9
43 lentigo maligna melanoma 10.2 MMP2 MMP9
44 bone cancer 10.1 IL6 MMP9 NOTCH1
45 senile ectropion 10.1 ELN MMP2 MMP9
46 acute transverse myelitis 10.1 IL6 MMP2 MMP9
47 transverse myelitis 10.1 IL6 MMP2 MMP9
48 autosomal recessive cutis laxa type i 10.1 EFEMP2 ELN TGFBR1 TGFBR2
49 cold agglutinin disease 10.1 CRP IL6
50 psammomatous meningioma 10.1 MMP2 MMP9
51 female reproductive system disease 10.1 IL6 MMP2 MMP9
52 reproductive system disease 10.0 IL6 MMP2 MMP9
53 tongue cancer 10.0 MMP2 MMP9 NOTCH1
54 mid-dermal elastolysis 10.0 ELN FBN1
55 pelvic organ prolapse 10.0 ELN MMP9 MYH11
56 pneumothorax 10.0 ELN FBN1 MMP2 MMP9
57 gastrointestinal system cancer 10.0 IL6 MMP2 MMP9 SMAD4
58 cerebral aneurysms 10.0 ELN MMP2
59 fundus dystrophy 10.0 ELN FBN1 MMP2 MMP9
60 esterase c 10.0
61 collagen disease 10.0 CRP FBN1 IL6
62 pancreas disease 10.0 CRP IL6 SMAD4
63 ischemia 10.0
64 pyelitis 10.0 CRP IL6 REN
65 pyomyositis 9.9 CRP NOTCH1
66 apnea, obstructive sleep 9.9 CRP IL6 REN
67 tongue squamous cell carcinoma 9.9 MMP2 MMP9 NOTCH1
68 cryopyrin-associated periodic syndrome 9.9 CRP IL6 NLRP3
69 obstructive jaundice 9.9 CRP IL6 REN
70 aortic valve disease 2 9.9 CRP ELN REN
71 subclavian steal syndrome 9.9 CRP NOTCH1
72 exanthem 9.9 CRP IL6 NLRP3
73 endocrine gland cancer 9.9 MMP2 MMP9 SMAD4
74 generalized atherosclerosis 9.9 APOE CRP
75 glucose metabolism disease 9.9 CRP IL6 REN
76 lung cancer susceptibility 3 9.9 MMP2 MMP9 SMAD4 TGFBR1 TGFBR2
77 ischemic heart disease 9.9 APOE CRP IL6
78 preterm premature rupture of the membranes 9.9 CRP IL6 MMP9
79 appendicitis 9.9 CRP IL6 MMP9
80 bone inflammation disease 9.9 CRP IL6 NLRP3
81 lyme disease 9.9 CRP IL6 MMP9
82 bacterial meningitis 9.9 CRP IL6 MMP9
83 chorioamnionitis 9.9 CRP IL6 MMP9
84 urinary system disease 9.9 CRP IL6 REN
85 coronary stenosis 9.9 APOE CRP IL6
86 chronic meningitis 9.8 CRP MMP9 NLRP3
87 acquired metabolic disease 9.8 CRP IL6 REN
88 ehlers-danlos syndrome, vascular type 9.8
89 aortic aneurysm, familial thoracic 4 9.8
90 mouth disease 9.8 CRP IL6 NOTCH1
91 proteasome-associated autoinflammatory syndrome 1 9.8 CRP IL6 MMP9
92 kawasaki disease 9.8 CRP IL6 MMP9
93 carotid stenosis 9.8 APOE CRP MMP9
94 pericardial effusion 9.8 CRP IL6 NLRP3 REN
95 pulmonary disease, chronic obstructive 9.8 CRP ELN IL6 MMP9
96 respiratory system disease 9.7 CRP IL6 MMP9
97 meningitis 9.7 CRP IL6 MMP9 NLRP3
98 arthropathy 9.7 CRP MMP2 NLRP3
99 coronary artery anomaly 9.7
100 spinal cord injury 9.7
101 chlamydia pneumonia 9.7
102 peripheral artery disease 9.7
103 chlamydia 9.7
104 horseshoe kidney 9.7
105 spinal cord infarction 9.7
106 stroke, ischemic 9.7 APOE CRP FBN1 REN
107 atherosclerosis susceptibility 9.7 APOE CRP IL6
108 nervous system disease 9.7 APOE CRP IL6 MMP9
109 carotid artery disease 9.7 APOE CRP MMP9 REN
110 periodontitis 9.6 CRP IL6 MMP2 MMP9
111 periodontal disease 9.6 CRP IL6 MMP2 MMP9
112 gastrointestinal system disease 9.6 CRP IL6 MMP2 MMP9
113 ewing sarcoma 9.6 IL6 MMP2 MMP9 TGFB2 TGFBR2
114 arteriosclerosis 9.6 APOE CRP ELN IL6 MMP9
115 cardiac conduction defect 9.5
116 renal cell carcinoma, nonpapillary 9.5
117 systemic lupus erythematosus 9.5
118 juvenile polyposis syndrome 9.5
119 hutchinson-gilford progeria syndrome 9.5
120 tuberous sclerosis 1 9.5
121 moyamoya disease 1 9.5
122 homocysteinemia 9.5
123 brittle bone disorder 9.5
124 coronary heart disease 1 9.5
125 aortic aneurysm, familial thoracic 7 9.5
126 moyamoya disease 5 9.5
127 aortic aneurysm, familial thoracic 8 9.5
128 aortic aneurysm, familial thoracic 9 9.5
129 diabetes mellitus 9.5
130 end stage renal failure 9.5
131 weill-marchesani syndrome 9.5
132 infective endocarditis 9.5
133 cardiac arrest 9.5
134 thrombosis 9.5
135 obstructive nephropathy 9.5
136 endocarditis 9.5
137 esophageal varix 9.5
138 cauda equina syndrome 9.5
139 patulous eustachian tube 9.5
140 tuberous sclerosis 9.5
141 syphilis 9.5
142 aortitis 9.5
143 situs inversus 9.5
144 mediastinitis 9.5
145 chronic intestinal vascular insufficiency 9.5
146 lupus erythematosus 9.5
147 col1a1/2-related osteogenesis imperfecta 9.5
148 rere-related disorders 9.5
149 aortic coarctation 9.5
150 fibrosing mediastinitis 9.5
151 dysphagia 9.5
152 cerebrovascular disease 9.5 APOE CRP IL6 MMP9 REN
153 esophageal cancer 9.4 CRP IL6 MMP2 MMP9 SMAD4 TGFBR2
154 vascular disease 9.4 APOE CRP ELN IL6 MMP9 REN
155 dilated cardiomyopathy 9.3 CRP IL6 MMP2 MMP9 REN TGFB2
156 large intestine cancer 9.3 CRP IL6 MMP2 MMP9 NOTCH1 SMAD4
157 myocardial infarction 9.2 APOE CRP IL6 MMP2 MMP9 REN

Graphical network of the top 20 diseases related to Aortic Disease:



Diseases related to Aortic Disease

Symptoms & Phenotypes for Aortic Disease

GenomeRNAi Phenotypes related to Aortic Disease according to GeneCards Suite gene sharing:

27 (showing 48, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.18 EFEMP2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.18 EFEMP2 MMP2 SMAD4 TGFB2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.18 TGFBR1 TGFBR2 SMAD4 TGFB2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.18 MMP2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.18 TGFB2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.18 TGFBR2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.18 CRP NOTCH1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.18 TGFBR2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.18 MMP2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.18 TGFBR2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.18 TGFBR2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.18 TGFB2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.18 NOTCH1 TGFB2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.18 CRP NOTCH1 TGFBR1 TGFBR2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.18 TGFBR2 EFEMP2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.18 CRP NOTCH1 EFEMP2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.18 TGFBR2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.18 TGFBR2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.18 TGFBR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.18 TGFBR2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-188 10.18 TGFBR2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.18 SMAD4
23 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.18 TGFB2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.18 MMP2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.18 NOTCH1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.18 SMAD4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.18 NOTCH1 TGFBR2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.18 TGFB2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.18 SMAD4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.18 EFEMP2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.18 TGFBR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.18 TGFBR1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.18 TGFBR2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.18 SMAD4 TGFB2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.18 SMAD4
36 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.18 SMAD4
37 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.18 CRP
38 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.18 TGFB2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.18 SMAD4
40 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.18 NOTCH1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.18 CRP MMP2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.18 NOTCH1 TGFBR2 EFEMP2
43 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.18 TGFBR2
44 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.18 NOTCH1 TGFBR2 SMAD4 TGFB2
45 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.18 SMAD4
46 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.18 TGFBR2 MMP2 SMAD4
47 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.18 TGFBR1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.18 TGFBR1

MGI Mouse Phenotypes related to Aortic Disease:

47 (showing 20, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.52 ACTA2 APOE CRP EFEMP2 FBN1 IL6
2 homeostasis/metabolism MP:0005376 10.47 ADAMTS1 APOE CRP FBN1 IL6 MMP2
3 growth/size/body region MP:0005378 10.43 ADAMTS1 APOE FBN1 IL6 MMP2 MMP9
4 mortality/aging MP:0010768 10.41 ADAMTS1 APOE EFEMP2 FBN1 IL6 MMP2
5 cellular MP:0005384 10.4 APOE EFEMP2 FBN1 IL6 MMP9 MYH11
6 immune system MP:0005387 10.4 APOE CRP FBN1 IL6 MMP2 MMP9
7 hematopoietic system MP:0005397 10.36 APOE FBN1 IL6 MMP2 MMP9 NLRP3
8 muscle MP:0005369 10.36 ACTA2 APOE EFEMP2 FBN1 IL6 MMP2
9 digestive/alimentary MP:0005381 10.35 APOE IL6 MMP9 MYH11 MYLK NLRP3
10 endocrine/exocrine gland MP:0005379 10.22 ADAMTS1 APOE FBN1 IL6 NOTCH1 SMAD4
11 nervous system MP:0003631 10.22 APOE FBN1 IL6 MMP2 MMP9 NLRP3
12 integument MP:0010771 10.21 APOE EFEMP2 FBN1 IL6 MMP9 MYH11
13 renal/urinary system MP:0005367 10.13 ADAMTS1 APOE FBN1 IL6 MMP9 MYH11
14 normal MP:0002873 10.07 EFEMP2 MMP2 MYLK NLRP3 NOTCH1 PRKG1
15 limbs/digits/tail MP:0005371 10.04 APOE EFEMP2 FBN1 MMP9 NLRP3 SMAD4
16 neoplasm MP:0002006 9.98 IL6 MMP2 MMP9 NOTCH1 SMAD4 TGFBR1
17 reproductive system MP:0005389 9.96 ADAMTS1 APOE FBN1 IL6 MMP9 NLRP3
18 respiratory system MP:0005388 9.9 APOE EFEMP2 FBN1 IL6 MMP2 MMP9
19 skeleton MP:0005390 9.77 APOE EFEMP2 FBN1 IL6 MMP2 MMP9
20 vision/eye MP:0005391 9.28 ACTA2 APOE EFEMP2 IL6 MMP2 MMP9

Drugs & Therapeutics for Aortic Disease

Drugs for Aortic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 240, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2
Morphine Approved, Investigational Phase 4,Phase 3 57-27-2 5288826
3
Ropivacaine Approved Phase 4,Phase 3 84057-95-4 175805 71273
4
Prednisolone Approved, Vet_approved Phase 4,Not Applicable 50-24-8 5755
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Not Applicable 302-25-0
6
Methylprednisolone Approved, Vet_approved Phase 4,Not Applicable 83-43-2 6741
7
Methylprednisolone hemisuccinate Approved Phase 4,Not Applicable 2921-57-5
8
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
9
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
10
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
11
Remifentanil Approved Phase 4 132875-61-7 60815
12
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
13
Angiotensin II Approved, Investigational Phase 4,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
14
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
15
Atenolol Approved Phase 4 29122-68-7 2249
16
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
17
Atorvastatin Approved Phase 4,Phase 3,Not Applicable 134523-00-5 60823
18
Eplerenone Approved Phase 4 107724-20-9 443872 150310
19
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
20
Clevidipine Approved, Investigational Phase 4,Not Applicable 167221-71-8
21
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
22
Calcium Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 7440-70-2 271
23
Prednisolone hemisuccinate Experimental Phase 4,Not Applicable 2920-86-7
24 Carbonic Anhydrase Inhibitors Phase 4
25 Natriuretic Agents Phase 4,Not Applicable
26 diuretics Phase 4,Not Applicable
27 Anticonvulsants Phase 4
28 Anesthetics Phase 4,Phase 3,Phase 1,Not Applicable
29 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
30 Analgesics, Opioid Phase 4,Phase 3
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
32 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
33 Narcotics Phase 4,Phase 3,Phase 2
34 Anesthetics, Local Phase 4,Phase 3
35 Methylprednisolone Acetate Phase 4,Not Applicable
36 Prednisolone acetate Phase 4,Not Applicable
37 cadexomer iodine Phase 4,Not Applicable
38 Autonomic Agents Phase 4,Not Applicable,Early Phase 1
39 Antimetabolites Phase 4,Phase 3,Not Applicable
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
41 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
42 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
43 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Not Applicable
44 Anesthetics, Intravenous Phase 4,Not Applicable
45 Platelet Aggregation Inhibitors Phase 4,Phase 2
46 Anesthetics, Inhalation Phase 4,Not Applicable
47 Hypnotics and Sedatives Phase 4,Not Applicable
48 Anesthetics, General Phase 4,Not Applicable
49 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1,Not Applicable
50 Tryptophan Phase 4
51 Antigen-Antibody Complex Phase 4
52 Angiotensin Receptor Antagonists Phase 4,Not Applicable
53 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
54 Angiotensinogen Phase 4,Not Applicable
55 Anti-Arrhythmia Agents Phase 4,Not Applicable
56 Sympatholytics Phase 4,Early Phase 1
57 Adrenergic beta-Antagonists Phase 4,Not Applicable,Early Phase 1
58 Angiotensin II Type 1 Receptor Blockers Phase 4,Not Applicable
59 Adrenergic Antagonists Phase 4,Phase 1,Early Phase 1
60 Neurotransmitter Agents Phase 4,Phase 2,Phase 1,Early Phase 1
61 Adrenergic beta-1 Receptor Antagonists Phase 4,Early Phase 1
62 Adrenergic Agents Phase 4,Phase 1,Early Phase 1
63 Giapreza Phase 4,Not Applicable
64 Lipid Regulating Agents Phase 4,Phase 3,Not Applicable
65 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Not Applicable
66 Anticholesteremic Agents Phase 4,Phase 3,Not Applicable
67 Hypolipidemic Agents Phase 4,Phase 3,Not Applicable
68 Fluorodeoxyglucose F18 Phase 4,Not Applicable
69 Calcium, Dietary Phase 4,Phase 2,Not Applicable
70 calcium channel blockers Phase 4,Phase 2,Not Applicable
71 Mineralocorticoids Phase 4
72 Diuretics, Potassium Sparing Phase 4
73 Mineralocorticoid Receptor Antagonists Phase 4
74 Adrenergic alpha-Agonists Phase 4
75 Adrenergic Agonists Phase 4
76 Adrenergic alpha-2 Receptor Agonists Phase 4
77
Acetaminophen Approved Phase 3 103-90-2 1983
78
leucovorin Approved Phase 3 58-05-9 143 6006
79
Azathioprine Approved Phase 3 446-86-6 2265
80
Mycophenolic acid Approved Phase 3 24280-93-1 446541
81
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
82
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
83
Ethanol Approved Phase 2, Phase 3 64-17-5 702
84
Prednisone Approved, Vet_approved Phase 2, Phase 3,Not Applicable 53-03-2 5865
85
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 441411 12560
86
Curcumin Approved, Experimental, Investigational Phase 2, Phase 3 458-37-7 969516
87
Tranexamic Acid Approved Phase 3 1197-18-8 5526
88
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
89
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
90
Melatonin Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 73-31-4 896
91 Antipyretics Phase 3
92 Antibiotics, Antitubercular Phase 3
93 Antimetabolites, Antineoplastic Phase 3,Not Applicable
94 Vitamin B9 Phase 3
95 glucocorticoids Phase 3,Phase 2,Not Applicable
96 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
97 Antitubercular Agents Phase 3
98 Alkylating Agents Phase 3,Phase 2,Not Applicable
99 Immunologic Factors Phase 3,Phase 2,Not Applicable
100 Antirheumatic Agents Phase 3,Phase 2,Not Applicable
101 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
102 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
103 Vitamin B Complex Phase 3
104 Folic Acid Antagonists Phase 3
105 Folate Phase 3
106 Nucleic Acid Synthesis Inhibitors Phase 3
107 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Not Applicable
108 Dermatologic Agents Phase 3,Phase 2,Not Applicable
109 Protective Agents Phase 2, Phase 3,Not Applicable
110 Gastrointestinal Agents Phase 3,Phase 2,Not Applicable
111 Anti-Inflammatory Agents Phase 2, Phase 3,Phase 3,Not Applicable
112 Antineoplastic Agents, Hormonal Phase 2, Phase 3,Not Applicable
113 Antioxidants Phase 2, Phase 3
114 Erythromycin stearate Phase 3
115 Cola Phase 3,Not Applicable
116 Erythromycin Estolate Phase 3
117 Erythromycin Ethylsuccinate Phase 3
118 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3,Not Applicable
119 Hemostatics Phase 2, Phase 3,Phase 3,Not Applicable,Early Phase 1
120 Coagulants Phase 2, Phase 3,Phase 3,Not Applicable,Early Phase 1
121 Antifibrinolytic Agents Phase 3,Early Phase 1
122 Antibodies Phase 3,Phase 2
123 Immunoglobulins Phase 3,Phase 2
124 Hypoglycemic Agents Phase 2, Phase 3,Phase 1,Not Applicable
125
Miconazole Approved, Investigational, Vet_approved Phase 2,Not Applicable 22916-47-8 4189
126
Infliximab Approved Phase 2 170277-31-3
127
Ticagrelor Approved Phase 2 274693-27-5 9871419
128
Perindopril Approved Phase 2 107133-36-8, 82834-16-0 107807
129
Amlodipine Approved Phase 2,Not Applicable 88150-42-9 2162
130
Doxycycline Approved, Investigational, Vet_approved Phase 2,Not Applicable 564-25-0 54671203
131
Abatacept Approved Phase 2 332348-12-6 10237
132
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
133
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
134
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
135
Nicardipine Approved, Investigational Phase 2 55985-32-5 4474
136
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
137 Calcineurin Inhibitors Phase 2,Not Applicable
138 Antifungal Agents Phase 2,Not Applicable
139 Cyclosporins Phase 2,Not Applicable
140 Purinergic P2Y Receptor Antagonists Phase 2
141 Purinergic P2 Receptor Antagonists Phase 2
142 Prolyl-Hydroxylase Inhibitors Phase 2
143
protease inhibitors Phase 2
144 HIV Protease Inhibitors Phase 2
145 Vasodilator Agents Phase 2,Phase 1,Not Applicable
146 arginine Phase 2
147 Angiotensin-Converting Enzyme Inhibitors Phase 2
148 Antimalarials Phase 2,Not Applicable
149 Antiparasitic Agents Phase 2,Not Applicable
150 Antiprotozoal Agents Phase 2,Not Applicable
151 Fluorides Phase 2,Not Applicable
152 Omega 3 Fatty Acid Phase 2
153 Soy Bean Phase 2
154 Antiviral Agents Phase 2
155 Adjuvants, Immunologic Phase 2
156 interferons Phase 2
157 Interferon-beta Phase 2
158 Narcotic Antagonists Phase 2
159 Interleukin-2 Phase 2
160 Plasminogen Phase 2
161 Fibrinolytic Agents Phase 2
162 Tissue Plasminogen Activator Phase 2
163 Antibodies, Monoclonal Phase 2
164
Hydrocortisone Approved, Vet_approved Phase 1,Not Applicable 50-23-7 5754
165
Hydrocortisone acetate Approved, Vet_approved Phase 1,Not Applicable 50-03-3
166
tannic acid Approved Phase 1,Not Applicable 1401-55-4
167
Benzocaine Approved, Investigational Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
168
Diphenhydramine Approved, Investigational Phase 1 147-24-0, 58-73-1 3100
169
Promethazine Approved, Investigational Phase 1 60-87-7 4927
170
Zinc Approved, Investigational Phase 1,Not Applicable 7440-66-6 32051
171 Urapidil Investigational Phase 1 34661-75-1
172 Hydrocortisone hemisuccinate Phase 1,Not Applicable
173 Hydrocortisone 17-butyrate 21-propionate Phase 1,Not Applicable
174 Adrenergic alpha-Antagonists Phase 1,Not Applicable
175 Radiopharmaceuticals Phase 1,Not Applicable
176 Adrenergic alpha-1 Receptor Antagonists Phase 1
177 Serotonin Agents Phase 1
178 Serotonin Receptor Agonists Phase 1
179 Ophthalmic Solutions Phase 1
180 Plasma-lyte 148 Phase 1
181 Insulin, Globin Zinc Phase 1,Not Applicable
182 insulin Phase 1,Not Applicable
183
Serotonin Investigational, Nutraceutical Phase 1 50-67-9 5202
184
Epinephrine Approved, Vet_approved ,Not Applicable 51-43-4 5816